法尼甾体X受体
化学
三萜
G蛋白偶联胆汁酸受体
羧酸盐
对抗
药理学
胆汁酸
2型糖尿病
内生
胆酸
敌手
脱氧胆酸
肠道菌群
生物化学
2型糖尿病
羧酸
立体化学
血脂异常
受体
结构-活动关系
作用机理
生物活性
铅化合物
化学合成
糖尿病
内分泌学
内科学
氯沙坦
作者
Li Zhang,Pan Tang,Yun Xu,Cheng Cheng,朱高峰,Lei Tang
标识
DOI:10.1021/acs.jmedchem.6c02247
摘要
Intestinal farnesoid X receptor (FXR) antagonism has emerged as a strategy to enhance endogenous glucagon-like peptide-1 (GLP-1) secretion and improve metabolic control in type 2 diabetes mellitus (T2DM). Dihydrooleanolic acid methyl ester (DKS26) served as the scaffold for the synthesis of 64 pentacyclic triterpene derivatives modified at the terminal carboxyl group and C-3/C-12 positions. Esterification of the terminal carboxylate emerged as a determinant of FXR antagonism, identifying 4l bearing a tetrazole-containing side chain and C-12 hydroxyl motif. Compound 4l antagonized FXR in a TR-FRET assay (IC50 = 11.79 μM), a fivefold improvement over DKS26. In NCI-H716 cells, 4l reduced NR0B2 (SHP) mRNA expression and markedly stimulated GLP-1 secretion. In HFD/STZ-induced diabetic mice, oral 4l improved glycemia, increased circulating GLP-1 and insulin, and alleviated dyslipidemia and organ injury markers. These findings establish the pentacyclic triterpene scaffold as a platform for FXR antagonism and identify 4l as a lead for further optimization.
科研通智能强力驱动
Strongly Powered by AbleSci AI